Investing Profile

Nanna Luneborg

InvestorVC
General Partner at Forbion
Photo of Nanna Luneborg, General Partner at Forbion

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Forbion General Partner
$100K - $5.0M
$1.5M
14
CompanyStageDateRound SizeTotal Raised
Sparrow Pharmaceuticals
Series BSep 2025$95M
$160M
Co-investors: Klaus Veitinger (OrbiMed), Zach Scheiner (RA Capital)
MapLight Therapeutics
Series DJul 2025$370M
$600M
Co-investors: Jim Trenkle (Sanofi Ventures)
Noema Pharma
Series BDec 2024$150M
Series BMar 2023$110M
$260M
Co-investors: Antoine Papiernik Papiernik (Soffinova Partners), Felice Verduyn - van Weegen (EQT Life Sciences)
Capstan Therapeutics
Series BMar 2024$180M
$280M
Co-investors: Michael Baran (Pfizer Venture Investments)
Inversago Pharma
Series COct 2022$69M
$110M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Elizabeth Douville (Amorchem), Marco Boorsma (Forbion)
F2G
Private EquityAug 2022$70M
$160M
Co-investors: Raj Parekh (Advent Life Sciences), Anja Konig (Novartis Venture Fund), Joseph Anderson (Soffinova Partners), Maha Katabi (Sofinnova Investments)
Numab
Series CMay 2021$110M
$110M
Lava Therapeutics
Series CSep 2020$83M
$100M
Co-investors: Guido Magni (Versant Ventures), Joël Jean-Mairet (Ysios Capital), Laia Crespo (Sanofi Ventures)